TY - JOUR
T1 - In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene
AU - Ruiz, Joaquim
AU - Marco, Francesc
AU - Sierra, Josep M.
AU - Aguilar, Lorenzo
AU - Garcia-Mendez, Elena
AU - Mensa, Josep
AU - Jiménez De Anta, M. Teresa
AU - Vila, Jordi
N1 - Funding Information:
We are indebted to Dr J.A.Vazquez for providing some of the analyzed strains. This work was performed thanks to a grant from Smith Kline-Beecham and by a grant FIS00/0632 from Fondo de Investigaciones Sanitarias. We would like to thank Servicio Cientifico Tecnicos of the University of Barcelona for their help in the DNA sequencing.
PY - 2003/7/1
Y1 - 2003/7/1
N2 - The MIC of gemifloxacin and five other quinolones was tested against 31 clinical isolates of Neisseria gonorrhoeae; strains were analyzed for the presence of mutations in both the gyrA and parC genes. Only seven strains were resistant to nalidixic acid due to a mutation in the gyrA gene but not in the parC gene, with six and two considered intermediate to ciprofloxacin and levofloxacin, respectively. The activity of gemifloxacin was similar to that of trovafloxacin and moxifloxacin, but was more active than nalidixic acid, ciprofloxacin or levofloxacin against the gyrA mutant strains. Gemifloxacin is a valid therapeutic alternative to treat infections with N. gonorrhoeae, retaining its activity against strains already presenting a mutation in gyrA.
AB - The MIC of gemifloxacin and five other quinolones was tested against 31 clinical isolates of Neisseria gonorrhoeae; strains were analyzed for the presence of mutations in both the gyrA and parC genes. Only seven strains were resistant to nalidixic acid due to a mutation in the gyrA gene but not in the parC gene, with six and two considered intermediate to ciprofloxacin and levofloxacin, respectively. The activity of gemifloxacin was similar to that of trovafloxacin and moxifloxacin, but was more active than nalidixic acid, ciprofloxacin or levofloxacin against the gyrA mutant strains. Gemifloxacin is a valid therapeutic alternative to treat infections with N. gonorrhoeae, retaining its activity against strains already presenting a mutation in gyrA.
KW - Gemifloxacin
KW - N. gonorrhoeae
KW - Quinolones
KW - gyrA
KW - parC
UR - http://www.scopus.com/inward/record.url?scp=0038385201&partnerID=8YFLogxK
U2 - 10.1016/S0924-8579(03)00083-9
DO - 10.1016/S0924-8579(03)00083-9
M3 - Artículo
C2 - 12842332
AN - SCOPUS:0038385201
SN - 0924-8579
VL - 22
SP - 73
EP - 76
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
IS - 1
ER -
